Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6713-6721

  Suzuki, Eiji ^a   Kapoor, Veena ^a   Jassar, Arminder Singh ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD11B ANTIGEN; GEMCITABINE;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL LOSS; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENE THERAPY; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOTHERAPY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; SUPPRESSOR CELL; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY; INTERFERON-BETA; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NECROSIS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CHEMOKINE; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 25144466458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0883     Document Type: Article

References (30)

1. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2001;51:293-8.
2. + T cells. Blood 2000;96:3838-46.
3. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza J. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 2001;166:6608-15.
4. Serafini P, De Santo C. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004;53:64-72.
5. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
6. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3-ζ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 1996;93:13119-24.
7. + myeloid cells. J Immunol 2001;166:5398-406.
8. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989-99.
9. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001;24:431-46.
10. Kusmartsev S, Fengdong C, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-9.
11. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002;62:2353-8.
12. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
13. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992;52:881-6.
14. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003;171:5051-63.
15. DeLong P, Tanaka T, Kruklitis R, et al. Use of cyclo-oxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
16. Odaka M, Sterman DH, Wiwrodt R, et al. Eradication of intraperitoneal and distant tumor by adenvirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-12.
17. Hui YF, Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997;54:162-70.
18. Hotchkiss RS, Tinsley KW, Hui JJ, et al. p53-dependent and -independent pathways of apoptotic cell death in sepsis. J Immunol 2000;164:3675-80.
19. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
20. Dong Z, Juang SH, Kumar R, et al. Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-β gene. Cancer Immunol Immunother 1998;46:137-46.
21. Tada H, Maron DJ, Choi EA, et al. Systemic IFN-βgene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001;108:83-95.
22. Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad.IFN-β during successful intraperitoneal tumor gene therapy. Mol Ther 2002;6:210-8.
23. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
24. Mazzoni A, Bronte V, Visintin A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependant mechanism. J Immunol 2002;168:689-95.
25. Young MR, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J Immunol 1996;156:1916-22.
26. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing suppressor myeloid cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
27. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000;164:2214-20.
28. + natural suppressor cells. Int J Cancer 1997;74:69-74.
29. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999;21:241-52.
30. Almand B, Resser J, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.